GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2
Public ClinicalTrials.gov record NCT05130255. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase 1 Trial With GD2-SADA:177Lu-DOTA Drug Complex in Patients With Recurrent or Refractory Metastatic Solid Tumors Known to Express GD2, Including Small Cell Lung Cancer, High Risk Neuroblastoma, Sarcoma and Malignant Melanoma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Patients with Small Cell Lung Cancer, High Risk Neuroblastoma, Sarcoma and Malignant Melanoma will be treated with GD2-SADA:177Lu-DOTA complex(The IMP is a two-step radioimmunotherapy, delivered as two separate products GD2-SADA and 177Lu-DOTA) to assess safety and tolerability
Study identification
- NCT ID
- NCT05130255
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 23 participants
Conditions and interventions
Conditions
Interventions
- GD2-SADA (0.3 mg/kg) and 177Lu-DOTA (30 mCi) Drug
- GD2-SADA (3 mg/kg) 177Lu-DOTA (30 mCi) Drug
- GD2-SADA (0.3 mg/kg) 177Lu-DOTA (200 mCi) Drug
- GD2-SADA (1 mg/kg) 177Lu-DOTA (200 mCi) Drug
- GD2-SADA (3 mg/kg) 177Lu-DOTA (200 mCi) Drug
- GD2-SADA (1 mg/kg) 177Lu-DOTA (30 mCi) Drug
- GD2-SADA (1 mg/kg) 177Lu-DOTA (100 mCi) Drug
Drug
Eligibility (public fields only)
- Age range
- 16 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 17, 2022 (Actual)
- Primary completion
- Mar 11, 2026 (Actual)
- Completion
- Mar 11, 2026 (Actual)
- Last update posted
- Jun 18, 2026
2022 – 2026
United States locations
- U.S. sites
- 8
- U.S. states
- 8
- U.S. cities
- 8
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| HonorHealth | Scottsdale | Arizona | 85258 | — |
| City of Hope National Medical Center | Duarte | California | 91010 | — |
| University of Chicago | Chicago | Illinois | 60637 | — |
| Corewell Health-BAMF Health | Grand Rapids | Michigan | 49503 | — |
| Memorial Sloan- Kettering Cancer Center | New York | New York | 10065 | — |
| Case Western Reserve University, Cleveland | Cleveland | Ohio | 44106 | — |
| UPMC Hillman Cancer Center | Pittsburgh | Pennsylvania | 15260 | — |
| University of Wisconsin-Madison | Madison | Wisconsin | 53705 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05130255, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 18, 2026 · Synced Oct 28, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05130255 live on ClinicalTrials.gov.